Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2016 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.88%

Madrigal Pharmaceuticals reported a loss per share of $0.67, which was in line with expectations, but no revenue figures were disclosed. The stock fell by 1.88% following the earnings report, reflecting investor concerns over the lack of guidance and clarity on future performance. The focus remains on their clinical programs, but uncertainty may weigh on investor sentiment.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.67	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook without providing detailed guidance. They emphasized their commitment to ongoing clinical development.

Management did not provide specific guidance for future quarters.

The company is focused on advancing its clinical programs.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.88%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.88%

Key numbers

Management commentary